HOME >> MEDICINE >> NEWS
Overactive bladder episodes completely controlled in 40 percent of elderly patients treated with once-a-day Oxybutynin

Elderly patients suffering from overactive bladder can significantly and safely reduce the symptoms of their condition by taking a once-a-day, extended-release formulation of oxybutynin chloride (Ditropan XL®), according to a study conducted by the Cleveland Clinic Foundation scheduled for presentation at the 2000 Annual Scientific Meeting of the American Geriatrics Society.

In the study, 40 percent of patients age 65 and older taking extended-release oxybutynin reported no incontinence episodes, while the average reduction in the weekly number of incontinence episodes for the elderly patients in the study was 82 percent.

"We found that elderly patients not only benefit by significantly reducing or eliminating their incontinence episodes when taking the extended-release formulation of oxybutynin, they also can do so safely and tolerate the drug very well. This is good news for this patient population, which frequently must deal with taking multiple medications and experiencing worrisome side effects," said Rodney Appell, M.D., study author and head, Section of Voiding Dysfunction and Female Urology at the Cleveland Clinic Urological Institute.

Overactive bladder is a common and chronic condition that affects an estimated 17 million Americans. The condition is characterized by urge urinary incontinence (sudden and involuntary loss of bladder control resulting in wetting accidents), urgency (the urgent need to empty the bladder) and frequency (frequent urination). Ditropan XL is the first and only once-a-day treatment for overactive bladder approved by the FDA and is marketed by ALZA Corporation and UCB Pharma.

For the study, investigators analyzed three clinical trials comparing different doses of extended-release and immediate-release oxybutynin in 159 patients older than 65 and in 261 patients age 18 to 65. All of the 420 patients suffered from overactive bladder.

During the clinical trials, researchers adjusted the
'"/>

Contact: Jim Armstrong, Cleveland Clinic
216-444-9455
Porter Novelli
19-May-2000


Page: 1 2 3

Related medicine news :

1. Overactive bladder symptoms affect sexual activity of women says Univ. of Pittsburgh study
2. New substance that improves the photodetection of bladder cancer gains market approval
3. Study examines three-day antibiotic regimens for treating bladder infection in women
4. New study tests amitriptyline for painful bladder syndrome
5. New test improves detection of bladder cancer
6. Faster, less expensive test proven more effective in detecting bladder cancer
7. Promise of bladder pacemaker for people with spinal cord injury
8. Use of estrogen therapy may increase risk for gallbladder disease
9. FDA approves Enablex for treatment of overactive bladder
10. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
11. Scientists begin validation study of test to detect recurrence of bladder cancer

Post Your Comments:
(Date:5/28/2015)... Falls Church, VA (PRWEB) May 29, 2015 ... Requirements, Best Practices and Innovative Approaches, **FDAnews Webinar**, ... p.m. EDT, http://www.fdanews.com/MDCybersecurityQA , Network connectivity ... devices, but it also exposes a minefield of ... condition to healthcare professionals, but can manufacturers be ...
(Date:5/28/2015)... On Monday, June 1, KORT, The Best in Rehab, ... Shelbyville, Kentucky . Clinic Director, Chad Flickinger, PT, MPT, CES, ... , “ Shelbyville is a growing community and KORT ... better serve the residents of Shelby County. At KORT, we ... possible by providing accessible and immediate care in a very ...
(Date:5/28/2015)... 29, 2015 Recently, KORT Richmond, 5006 Atwood ... regain their quality of life. The program works with those ... one for years, but are still having difficulty. , According ... million people living with limb loss in the United States. ... including diabetes and peripheral arterial disease – trauma (45%) and ...
(Date:5/28/2015)... Calgary, AB (PRWEB) May 28, 2015 ... the world and all over the United States. There ... of heart disease, who can experience symptoms of angina ... cardiac medications, heart stents and/or bypass surgery. , “No ... angina due to coronary artery disease that is considered ...
(Date:5/28/2015)... May 28, 2015 Cosmetic Town Journal ... surgeons and patients alike. You can find information on ... and body contouring. Readers can directly connect to the ... experience from the ground up. , The continued addition ... the community to grow and getting it closer to ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 2Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 3Health News:KORT Physical Therapy Opens New Clinic In Shelbyville, Kentucky 2Health News:KORT Physical Therapy Opens New Clinic In Shelbyville, Kentucky 3Health News:KORT Richmond Physical Therapy Adds New Program to Help Amputees 2Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 2Health News:New York Cosmetic Doctors Now in Cosmetic Town 3
(Date:5/28/2015)... May 28, 2015  Eli Lilly and Company (NYSE: ... announced cash tender offer for up to $1.6 billion aggregate ... Holders of notes who tendered, and did not validly ... New York City time, on May 27, 2015 ... by Lilly, are eligible to receive the total consideration. The ...
(Date:5/28/2015)... , May 28, 2015 Zimmer Holdings, ... it has finalized agreements with buyers to divest in ... Unicompartmental High-Flex Knee System assets, Biomet Discovery® Elbow System ... are in furtherance of Zimmer,s pending acquisition of Biomet, ... Zimmer continues to work constructively with the Bureau of ...
(Date:5/28/2015)... , May 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ... for the second quarter and three and six months ended ... Canadian dollars and in accordance with International Financial Reporting Standards ... recorded a net loss of $5.9 million ($0.35 per common ... compared to a net loss of $0.4 million ($0.03 per ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
Cached News: